SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved diagnostic test for PD-L1 ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
NEW ROCHELLE, N.Y., March 5, 2025 /PRNewswire/ -- A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models (LLMs) to rapidly extract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results